Summer Sale
50% off Premium Yearly
NASDAQ:AMGN
Amgen Inc. (AMGN)
Financials 
Technical Analysis 
Jun 15, 2026, 12:00 amThis summary was created by AI, based on 20 opinions in the last 12 months.
Amgen Inc. is generally perceived as a well-managed and innovative biotech company, characterized by a strong portfolio with 15 products witnessing double-digit revenue growth. Analysts note the company's potential due to its attractive valuation, with a forward P/E ratio under 20x and a solid dividend yield around 3.23% to 3.46%. Investors are optimistic about Amgen's development of its GLP-1 drug, which is currently in phase 3 testing and has the potential to be a game-changer in the weight-loss market. Despite facing some challenges, including trial misses and growing competition, many experts recommend holding or buying shares, highlighting its safety as a large-cap biotech investment. Overall, Amgen is seen as a stable choice for investors looking for exposure to the biotech sector amidst a fluctuating healthcare market.
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
